Epithelial Ovarian Cancer – Pipeline Review, H2 2016
- Pages: 507
- Published: November 2016
- Report Code: GMDHC8712IDB
Global Markets Direct’s, ‘Epithelial Ovarian Cancer – Pipeline Review, H2 2016’, provides an overview of the Epithelial Ovarian Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Epithelial Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epithelial Ovarian Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer
The report reviews pipeline therapeutics for Epithelial Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Epithelial Ovarian Cancer therapeutics and enlists all their major and minor projects
The report assesses Epithelial Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Epithelial Ovarian Cancer
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
AbbVie Inc
Adaptimmune Therapeutics Plc
Amgen Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Bayer AG
BioNumerik Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Celldex Therapeutics Inc
Celon Pharma Sp z oo
Celsion Corp
CerRx Inc
Cerulean Pharma Inc
Clovis Oncology Inc
Dr. Reddy's Laboratories Ltd
EirGenix Inc.
Eisai Co Ltd
Eli Lilly and Company
Esperance Pharmaceuticals Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Gene Techno Science Co Ltd
Genentech Inc
Genor BioPharma Co Ltd
Glycotope GmbH
Ignyta Inc
ImmunoGen Inc
Incyte Corp
Innate Immunotherapeutics Ltd
Johnson & Johnson
Juno Therapeutics Inc
Mabion SA
MabVax Therapeutics Holdings Inc
Mateon Therapeutics Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Mycenax Biotech Inc
Novartis AG
Novogen Ltd
Oasmia Pharmaceutical AB
OBI Pharma Inc
Oncobiologics Inc
Oncolix Inc
Oncolytics Biotech Inc
Oxford BioMedica Plc
OXIS International, Inc.
Pharma Mar SA
Prima BioMed Ltd
PsiOxus Therapeutics Ltd
Rgenix Inc
Richter Gedeon Nyrt
Sanofi
Sanofi Pasteur SA
Shenzen SiBiono GeneTech Co., Ltd.
Sotio as
TapImmune Inc
Tara Immuno-Oncology Therapeutics LLC
Tesaro Inc
TetraLogic Pharmaceuticals
Tyrogenex Inc
VentiRx Pharmaceuticals Inc
Verastem Inc
Vyriad Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.